NOVATO, Calif., May 14, 2019 /PRNewswire/ -- QT Ultrasound® has been invited to showcase an evolution in ultrasound technology at one of the most prestigious industry events. The Acoustical Society of America (ASA) has invited James Wiskin, Ph.D, Principal Scientist, to lecture at their 177th Meeting, taking place in Louisville, Kentucky, May 13-17.
In the special conference session, Inverse problems in Biomedical Ultrasound I, Dr. Wiskin will be presenting on "Full Wave 3D Transmission Tomography: 21st Century Technology for Whole Body Imaging." Word has spread in the ultrasound community that QT Ultrasound's clinical and research team have made remarkable strides in orthopedic and whole-body imaging. In support of those developments, the presentation will show quantitative accuracy of tissue parameters in the presence of bone and air (validated against literature values), previously thought to have been impossible. Further evidence will show the ability of Quantitative Transmission Ultrasound (QTU) to image regions which do not show up in Magnetic Resonance Images (MRI). Fusion with registered speckle free compounded reflection images leads to novel biomarkers for tissue and concomitant segmentation/classification algorithms. This and the lack of ionizing radiation and contrast agents point towards QTU as a viable technology for whole body, breast and orthopedic imaging.
Dr. Wiskin's lecture will discuss the clinical value of 3D quantitative tissue characterization and how whole body and orthopedic images are constructed using inherently 3D reconstruction algorithms and 3D data. Wiskin noted "I believe the clinical importance of 3D transmission ultrasound is understood by the ASA, which is the reason they sought out this presentation for their annual conference. It's an honor to share our research findings and developments with scientists and engineers that are at the forefront of medical ultrasound research."
Conference attendees are encouraged to attend this valuable educational session on Thursday, May 16, at 8:00AM. QT ultrasound's quantitative imaging of tissue parameters by solving inverse scattering and related problems, will also be mentioned on May 15, at 2:05PM in an ASA summary lecture of recent notable developments in biomedical ultrasound.
QT Ultrasound's technology has already received FDA 510(k) clearance for breast imaging for which the company's research has demonstrated a higher degree of accuracy than mammography or handheld ultrasound at identifying certain breast structures and that it produces image contrast comparable to a typical MRI.
About QT Ultrasound
QT Ultrasound® is a privately held company engaged in the research, development, and commercialization of an innovative automated imaging system producing high-resolution transmission ultrasound images. The company has received FDA 510(K)clearance for its QT Ultrasound Breast Scanner, and the National Institutes of Health (NIH) awarded over $15 million in funding to continue QT Ultrasound research. The company's clinical trials have been conducted at prestigious institutions in the US and Europe and include ongoing trials at the Marin Breast Health Trial Center in Novato, California. QTscans are now available commercially through the breast imaging centers of QTbreasthealth™.
The QT Ultrasound Breast Scanner is indicated for use as an ultrasonic imaging system to provide reflection-mode and transmission-mode images of a patient's breast. The device is not intended to be used as a replacement for screening mammography.
QT Ultrasound Media Contact:
SOURCE QT Ultrasound